

Q2  2020
QUARTERLY REPORT

DIGNITANA
Clinically superior scalp cooling

**Dignitana holds
steady during
challenging market**

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Dignitana holds steady during challenging market

Financial highlights

- Group revenue in Q2 2020 amounted to 11 876 TSEK (12 002 TSEK), a decrease of 1 percent over the same period in 2019 and a decrease of 5 percent over Q1 2020.
- EBITDA in Q2 2020 amounted to -5 066 TSEK (-5 165 TSEK), an improvement of 2 percent over the same period in 2019 and an improvement of 42 percent compared to Q1 2020.
- Earnings per share in Q2 2020 is -0.17 SEK compared to -0.16 SEK in the same period 2019.
- Average Daily Treatment Revenue (ADTR)* was 126 TSEK (99 TSEK), an increase of 27 percent over the same period in 2019 and a 7 percent increase over Q1 2020.

Significant events during the period

- The Company obtained an unsecured loan in the amount of \$353 800 USD from the Payroll Protection Program, a COVID-19 economic stimulus initiative in the United States. All requirements have been met for the loan to be fully forgiven.
- With the final \$500 000 USD received in the second period, funding was completed for a new loan from Union Business Leasing in the total amount of \$1,5 million USD.
- The Annual General Meeting in Lund resolved all proposed items in accordance with the announced proposals.
- Dignitana signed master contracts with Hartford HealthCare and American Oncology Network in the U.S.

Significant events after the period

- The Company secured an unsecured loan from Adma Förvaltnings AB in the amount of 20 000 TSEK.
- Dignitana announced Redeye is now Certified Adviser.
- The Company appointed a new Chief Financial Officer who will join Dignitana in November.
- Dignitana was selected as scalp cooling provider by Nuffield Health in United Kingdom.
- Dignitana added a Regional Director in Europe to support the Company's expanded focus in this area.

Key Ratios

DIGNITANA GROUP	Q2 2020	Q2 2019	Q1-Q2 2020	Q1-Q2 2019	Full year 2019
Net revenues, TSEK	11 423	11 945	22 816	21 182	40 699
Total revenues, TSEK	11 876	12 002	24 353	22 109	42 546
Net profit after financial items, TSEK	-9 528	-7 474	-22 283	-12 744	-37 950
Cash and bank balances, TSEK	7 484	11 468	7 484	11 468	19 433
Earnings per share before and after dilution, SEK	-0,17	-0,16	-0,40	-0,27	-0,76
Average Daily Treatment Revenue*, TSEK	126	99	122	94	107

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

"The relative consistency achieved from Q1 to Q2, despite COVID-19, is directly attributable to our superior DigniCap Delta product, our new business model, and our work to increase awareness and availability of scalp cooling."

William Cronin, CEO Dignitana AB

Dignitana holds steady during challenging market

2020 has been an unprecedented year, both for Dignitana and our communities around the globe. There is no doubt that COVID-19 has dramatically impacted not only our daily lives but our business and the provision of healthcare services the world over. In the midst of the pandemic, we are today reporting a one percent decline in our revenue over Q2 2019. The market conditions experienced during this quarter were unlike anything ever seen and difficult to navigate. Most importantly, for the 18th consecutive quarter our revenue in the U.S. showed a quarter over quarter increase. Despite the significant changes to operating practices due to the pandemic, the company grew U.S. revenue by 8 percent over the first period of 2020. The relative consistency achieved from Q1 to Q2, despite COVID-19, is directly attributable to:

- our superior DigniCap Delta product
- our new business model utilizing pay-per treatment and the sale of disposables
- our work to increase awareness and availability of scalp cooling.

In our April teleconference I said at some point we anticipated there would be an impact from COVID-19 on our revenue – and that the timing and significance of the impact would be based primarily on how long this pandemic lasts. Now, nearly five months later, daily life is returning to a new kind of normal in Europe while the U.S. continues to struggle with new cases.

Market conditions and growth

In the United States our highest revenue-generating markets are dense urban areas where COVID-19 remains a significant challenge for healthcare providers. All major U.S. metropolitan areas are still under public health directives including our three key states: New York, California, and Florida. As the company has grown, we have achieved a reasonable level of geographic diversity with DigniCap installations in 30 states from coast to coast. Several states that were less impacted by COVID-19 showed increases in usage and revenue over the first period of this year and the growth in these regions completely offset the revenue declines from our larger, more densely populated markets. Average Daily Treatment Revenue (ADTR), a U.S. metric we track very closely and first released last quarter, showed a solid increase of 7 percent for the period.

In response to the pandemic some U.S. sites instituted protocols restricting access to the oncology facilities or limiting patient usage of DigniCap equipment. Some of these strict protocols are ongoing, and in light of recent rising infection rates, most facilities are taking every precaution possible before resuming normal business activities. As a result of the pandemic protocols barring new equipment installations our equipment deliveries dropped by 38 percent (48 versus 78) from Q1 to Q2 this year. To address these challenges, we have initiated an extensive digital training program that is helping us maintain contact with and improve processes at our partner sites. We are shipping

devices to existing U.S. customers as their volumes increase and have received orders for new U.S. facilities that will ship in the third quarter.

In Europe the pandemic recovery is progressing, and most healthcare facilities are resuming normal activities. Interest in the benefits offered by DigniCap Delta has increased and after the period we added a new Regional Director to focus on the tremendous growth potential in the area.

The pandemic has slowed sales in other key markets around the globe, but we continue to aggressively pursue and advance several meaningful opportunities.

Monitoring progress and modifying operations

This global situation has presented the Company with an unforeseen opportunity to fine-tune internal processes and take a deep dive into several key areas of our business. We have made organizational changes to mitigate the financial strain the virus has placed on our growth trajectory and taken actions to ensure that when business levels return to some semblance of normalcy we will be prepared and in position to actively pursue expansion.

Of note after the period, in July the Company received an unsecured loan from Adma Förvaltnings AB, Dignitana's largest shareholder, which will support our aggressive growth plans into 2021 as market conditions allow.

Moving forward

Globally, we are focused on several key markets where interest and access are beginning to open again. The partnership recently announced with Nuffield Health in the United Kingdom is a prominent measure of growth as we utilize our best in class DigniCap Delta to extend our footprint in more markets.

Entering the third period we are advancing aggressive sales strategies to support our goals of acquiring five percent of the addressable market in the U.S. within three years and ten percent within five years. Breakeven continues to be the most important goal that we are working toward.

The duration and severity of the pandemic cannot be determined yet. Dignitana will continue to take the actions necessary to ensure our patients and partner sites receive the level of service and commitment from us that they require and welcome the day when life returns to a more normal and predictable phase. Even in these unprecedented times Dignitana is moving forward, with a solid foundation for growth and bright prospects to realize our full potential.



William Cronin, CEO
Dignitana AB



The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. In the United States and Dignitana S.r.l. in Italy. Redeye is Certified Adviser.


The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals in Australia and Israel.

Business model

The Company has five primary revenue streams: treatment fees from patients (pay-per-treatment using leased machines), machine sales, service agreements, leasing fees and product disposables and supplies. In the United States the largest opportunity for growth is through the pay-per-treatment model. For global markets that do not have the pay-per-treatment model, the focus is on creating a more

sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The new, single patient, DigniCap Delta is generating significant additional interest from the medical community and we believe the trend towards greater infection control standards will generate additional momentum for the Company going forward.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1.3 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1.7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world. In the U.S. Dignitana supports legislative initiatives to make scalp cooling readily accessible for all patients.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company is currently in discussions to initiate several new studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients.

The DigniCap Scalp Cooling System is currently available in 40 countries. The DigniCap C3 device has been marketed worldwide since 2009. DigniCap Delta received CE Marking in March, U.S. FDA clearance in June and TGA (Australia) clearance in September 2019. The transition to DigniCap Delta is underway with current U.S. customers and the roster of new U.S. customers is growing rapidly. Outside the U.S., the next generation DigniCap Delta is already in use in Australia, Italy, Spain, the United Kingdom and Israel and will soon be available to patients in Bahrain and Germany.



Financial information and comments

Revenue – Dignitana Group

Our transition to the new Delta unit and business model continue now with just over 60 percent our U.S sites having at least one Delta unit and units being shipped to more sites overseas. Group revenues are generated by direct sales of systems, pay-per-treatment fees, cap and patient kit sales, leased systems, service agreements and other revenue. Dignitana Group total revenue and other income during the second quarter 2020 amounted to 11 876 TSEK, which is a decrease of 1 percent compared to the same period last year.

Dignitana revenue and costs are comprised of different currencies such as U.S. Dollars, Euros, SEK, and other currencies. Foreign exchange translation differences are found on the Income Statement in Other Income, Other Operating Expenses and Financial Income and Expenses.

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market, Dignitana does not sell devices directly to the end customer as various lease models are employed.

Cost of goods sold for the Group decreased to 1 576 TSEK for the second quarter of 2020. Gross margin for the first half of 2020 increased compared to the same period previous year.

Profit and Loss – Dignitana Group

Group EBIT for the second quarter was -9 030 TSEK compared to -7 105 TSEK in the same period in 2019. Net profit after financial items was -9 528 TSEK compared to -7 474 TSEK for the same period last year. The decline in EBIT was due to increases in depreciation and amortization expenses associated with increased number of DigniCap Delta units installed in the U.S. and amortization related to the development cost for the Delta device in combination with higher personnel expenses.

Earnings per share for the second quarter of 2020 amount to -0,17 SEK, which is in line with the second quarter of 2019.

Cash flow and liquidity

At close of the period the Group's cash position was 7 484 TSEK. The Board of Directors and management are continually and actively working to safeguard liquidity and the continued financing of operations under the most advantageous terms possible.

After the end of Q2 2020, the Company raised new loans totaling 20 000 TSEK on normal market terms from Adma Förvaltnings AB.



Revenue – Dignitana Parent Company

Dignitana Parent Company total revenues during the second quarter amounted to 8 220 TSEK which is a decrease of 2 percent compared to the same period last year.

Other Income includes foreign exchange gains on accounts receivable and accounts payable and the revenue associated with the sublease of a portion of the Lund office space.

Profit and Loss – Dignitana Parent Company

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market Dignitana does not sell the device directly to the end customer as various lease models are employed.

Cost of goods sold for the Parent Company decreased to 1 021 TSEK for the second quarter 2020. For the first half of 2020 the cost of goods sold was 2 999 TSEK which is in line with the same period previous year, 3 082 TSEK.

Parent EBIT for the second quarter was -4 014 TSEK compared to -2 723 TSEK in the same period in 2019.

Net profit after financial items was -4 121 TSEK compared to -2 862 TSEK for the same period last year. The decline in both EBIT and Net profit was due primarily to increases in depreciation and amortization expenses associated with the amortization of the development costs for the Delta system and increased number of DigniCap Delta units installed in the United States.

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by a number of factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The nonconclusive list of the Company's risks concerns include but are not limited to: Patents, Key Personnel, Growth, Management, Restructuring, Development Costs, Competitors, Dependence on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Pandemic Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the 2019 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Staff

During the second quarter Dignitana had, on average, 26 persons employed.

The share

The total number of outstanding shares is 55 059 155 and earnings per share is - 0,17 SEK. The share has been listed on Nasdaq First North Growth Market in Stockholm since 30 November 2011 after having been listed at Spotlight Market in Stockholm since June 2009. It is traded under the DIGN ticker.

At the Extraordinary General Shareholders meeting in February 2020 it was resolved to issue and transfer

warrants to key persons in Dignitana Inc. in accordance with the proposal by the Board of Directors. If all the warrants outstanding under the 2017/2020 program would be converted in full the total dilution in number of shares and votes is approximately 4,5 percent. Warrants are given free of charge and costs will be incurred in second half of 2020.

Redeye is the Company's Certified Adviser.

Largest Shareholders

30 JUNE 2020	HOLDINGS	PERCENTAGE
ADMA FÖRVALTNINGS AB (Greg Dingizian)	14 364 729	26,09 %
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	4 466 141	8,11 %
CBLDN-UBS FINANCIAL SERVICES INC (William Cronin & others)	4 292 985	7,80 %
EUROSUND AB (Johan Stormby)	3 058 036	5,55 %
SKANDIA, FÖRSÄKRINGS (Greg Dingizian & others)	1 651 900	3,00 %
IBKR FINANCIAL SERVICES AG, W8IMY	1 622 573	2,95 %
POURSAMAD, AMIR	1 520 095	2,76 %
NORDNET PENSIONS FÖRSÄKRING AB	1 082 866	1,97 %
RÜLF, SEMMY	1 015 058	1,84 %
PERSSON, RUTGER	993 310	1,80 %
TOTAL	34 067 693	61.87 %
OTHER SHAREHOLDERS	20 991 462	38.13 %
TOTAL	55 059 155	100 %

Source: Euroclear

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 20 August 2020

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Ingrid Atteryd Heiman
Board member

Pontus Kristiansson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

This interim report has not
been audited by the Company auditors.

Income Statement – Dignitana Group, SEK

DIGNITANA GROUP	Q2 2020	Q2 2019	Q1-Q2 2020	Q1-Q2 2019	Full year 2019
Operating Income					
Revenue	11 423 181	11 945 286	22 816 263	21 181 910	40 699 211
Other income	452 386	57 599	1 536 950	927 419	1 846 817
Total Operating Income	11 875 567	12 002 885	24 353 212	22 109 329	42 546 028
Cost of Goods Sold					
Goods for Resale	-1 576 188	-3 372 686	-5 575 246	-5 536 166	-11 559 218
GROSS PROFIT	10 299 379	8 630 199	18 777 966	16 573 163	30 986 810
Expenses					
Operating expense	-7 261 711	-8 602 584	-17 301 670	-14 673 174	-34 984 714
Personnel expense	-6 802 920	-5 256 385	-13 453 033	-9 916 021	-21 367 162
Other operating expenses	-1 300 615	63 467	-1 851 122	51 239	-894 891
Total operating expenses	-15 365 246	-13 795 502	-32 605 825	-24 537 955	-57 246 767
Operating profit (loss) - EBITDA	-5 065 867	-5 165 303	-13 827 859	-7 964 792	-26 259 957
Depreciation of tangible and intangible assets	-3 963 986	-1 939 778	-7 683 444	-3 850 359	-10 266 997
Operating profit (loss) after depreciation - EBIT	-9 029 853	-7 105 081	-21 511 303	-11 815 151	-36 526 954
Result from financial investments					
Interest income and similar items	-10 866	644	31 606	1 482	102 590
Interest expenses and similar items	-487 325	-369 787	-803 616	-930 295	-1 525 440
Total income from financial investments	-498 191	-369 143	-772 011	-928 813	-1 422 850
Net profit after financial items	-9 528 044	-7 474 224	-22 283 313	-12 743 964	-37 949 804
Corporate Taxes	0	-6 281	0	-57 404	-85 413
Results for the Period	-9 528 044	-7 480 505	-22 283 313	-12 801 368	-38 035 217

Balance Sheet – Dignitana Group, SEK

DIGNITANA GROUP	2020-06-30 2020	2019-06-30 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	19 193 157	25 724 339	22 594 795
<u>Tangible assets</u>			
Equipment, tools and installations, net	29 202 601	12 416 373	22 214 084
Total Fixed Assets	48 395 758	38 140 712	44 808 879
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6 785 134	5 921 719	9 391 105
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	4 018 151	5 424 118	4 409 995
Current Tax Assets	21 404	-333 335	269 467
Other Current Receivables	1 217 483	253 952	844 666
Prepaid expenses and accrued income	2 571 569	1 082 638	2 331 781
Cash and Bank Balances	7 483 745	11 468 142	19 432 901
Total Current Assets	24 895 813	23 817 234	36 679 915
Total Assets	73 291 571	61 957 946	81 488 794
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55 059 155 shares par value SEK 1, previous year 40 528 224)	55 059 155	48 599 155	55 059 155
Fund for development expenses	17 202 163	20 945 528	19 218 072
<u>Non-restricted equity</u>			
Other non-restricted equity	-15 864 317	-14 711 011	18 860 805
Results for the period	-22 283 313	-12 801 368	-38 035 217
Total Equity	34 113 688	42 032 304	55 102 816
Long Term Liabilities			
Other long term liabilities	5 851 080	594 591	1 917 208
Total Long Term Liabilities	5 851 080	594 591	1 917 208
Current Liabilities			
Accounts payable	10 323 950	9 440 152	8 888 418
Other current liabilities	4 176 783	873 676	3 401 023
Liabilities to credit institutions	10 627 564	5 760 514	5 505 968
Accrued expenses and deferred income	8 198 506	3 256 709	6 673 362
Total current liabilities	33 326 803	19 331 051	24 468 771
Total liabilities	39 177 883	19 925 642	26 385 979
Total Equity and Liabilities	73 291 571	61 957 946	81 488 794

Changes in Equity – Dignitana Group, SEK

DIGNITANA GROUP	Q1-Q2 2020	Q1-Q2 2019	Full year 2019
Opening balance	55 102 816	54 965 116	54 965 116
New Share Issue	0	0	41 990 000
Warrants	189 000	0	0
Issue expenses	218 010	0	-3 380 915
Translation difference on consolidation	887 175	-131 444	-436 168
Results through the end of the period	-22 283 313	-12 801 368	-38 035 217
Closing balance	34 113 688	42 032 304	55 102 816

Statement of Cash Flows – Dignitana Group, SEK

DIGNITANA GROUP	Q2 2020	Q2 2019	Q1-Q2 2020	Q1-Q2 2019	Full year 2019
Operating Activities					
Operating income before financial items	-9 029 853	-7 105 081	-21 511 303	-11 815 151	-36 526 954
Adjustments for items not affecting cash flows	3 963 986	1 939 778	7 683 444	3 850 359	9 666 997
Interest received	10 754	644	30 837	1 481	102 589
Interest paid	-406 245	-369 787	-699 174	-930 295	-1 525 440
Income tax paid	0	-340 160	0	-421 886	-425 058
	-5 461 358	-5 874 607	-14 496 196	-9 315 492	-28 707 866
Changes in inventories	-780 841	428 903	-181 472	386 817	-3 082 569
Changes in other current receivables	-570 164	2 015 921	-514 029	1 432 527	467 589
Changes in other current liabilities	5 568 611	1 622 105	3 793 592	-600 266	3 988 327
Cash flows from operating activities	-1 243 752	-1 807 679	-11 398 105	-8 096 414	-27 334 519
Investing Activities					
Acquisition of fixed assets	-3 536 147	-5 463 500	-11 257 481	-8 214 565	-20 699 370
Cash flows from investing activities	-3 536 147	-5 463 500	-11 257 481	-8 214 565	-20 699 370
Financing activities					
New share issue	0	0	0	9 846 053	51 836 053
Issuance costs	218 010	0	218 010	-525 000	-3 905 915
Warrants	189 000	0	189 000	0	0
Liabilities to credit institutions	2 328 226	-3 009 425	9 347 943	-3 832 733	-2 764 662
Cash flows from financial activities	2 735 236	-3 009 425	9 754 953	5 488 320	45 165 476
Cash flows in the period	-2 044 663	-10 280 604	-12 900 633	-10 822 659	-2 868 413
Cash and cash equivalents at start of the period	8 768 198	21 715 092	19 432 901	22 160 875	22 160 875
Translation difference on cash and cash equivalents	760 210	33 654	951 476	129 925	140 439
Cash and cash equivalents Period End	7 483 745	11 468 141	7 483 745	11 468 141	19 432 901

Income Statement – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q2 2020	Q2 2019	Q1-Q2 2020	Q1-Q2 2019	Full year 2019
Operating Income					
Revenue	7 599 778	8 354 071	15 346 226	14 574 570	27 114 785
Other income	620 690	57 599	1 705 254	927 419	1 846 817
Total Operating Income	8 220 468	8 411 670	17 051 480	15 501 989	28 961 602
Cost of Goods Sold					
Goods for Resale	-1 020 802	-1 986 111	-2 998 857	-3 082 469	-6 001 626
GROSS PROFIT	7 199 666	6 425 559	14 052 623	12 419 520	22 959 976
Expenses					
Operating expense	-5 547 276	-6 925 637	-14 991 202	-15 487 714	-33 682 777
Personnel expense	-477 500	-439 945	-1 019 281	-946 515	-1 573 393
Other operating expenses	-1 297 850	63 467	-1 842 381	51 239	-580 237
Total operating expenses	-7 322 626	-7 302 115	-17 852 864	-16 382 990	-35 836 407
Operating profit (loss) - EBITDA	-122 960	-876 556	-3 800 241	-3 963 470	-12 876 431
Depreciation of tangible and intangible assets	-3 891 243	-1 846 824	-7 535 194	-3 697 238	-9 950 466
Operating profit (loss) after depreciation - EBIT	-4 014 203	-2 723 380	-11 335 435	-7 660 707	-22 826 897
Result from financial investments					
Interest income and similar items	-21 620	0	0	0	0
Interest expenses and similar items	-85 302	-138 786	-121 537	-487 809	-734 977
Total income from financial investments	-106 922	-138 786	-121 537	-487 809	-734 977
Net profit after financial items	-4 121 125	-2 862 166	-11 456 972	-8 148 516	-23 561 874
Corporate Taxes	0	0	0	0	0
Results for the Period	-4 121 125	-2 862 166	-11 456 972	-8 148 516	-23 561 874

Balance Sheet – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	2020-06-30 2020	2019-06-30 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	19 162 121	25 707 369	22 561 837
<u>Tangible assets</u>			
Equipment, tools and installations, net	28 789 441	11 907 407	21 719 293
<u>Financial assets</u>			
Participations in group companies	522 094	522 094	522 094
Long Term Receivable from group companies	473 410	463 565	0
Total Fixed Assets	48 947 066	38 600 435	44 803 224
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6 081 177	5 686 237	8 473 678
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	892 201	1 934 893	1 277 591
Current Receivables from group companies	7 740 196	887 610	7 366 642
Current Tax Assets	21 404	225 262	314 450
Other Current Receivables	1 012 988	242 513	831 934
Prepaid expenses and accrued income	609 156	601 925	501 518
Cash and Bank Balances	1 856 668	8 464 536	17 116 918
Total Current Assets	21 012 117	18 042 976	35 882 731
Total Assets	69 959 183	56 643 411	80 685 955
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55,059,155 shares par value SEK 1, previous year 40,528,224)	55 059 155	48 599 155	55 059 155
Fund for development expenses	17 202 163	20 945 527	19 218 072
<u>Non-restricted equity</u>			
Retained earnings	-73 365 799	-14 226 727	-51 819 834
Share premium reserves	83 783 504	0	83 594 504
Issue expense	-11 906 850	0	-12 124 860
Results for the period	-11 456 972	-8 148 519	-23 561 874
Total Equity	59 315 201	47 169 436	70 365 163
Current Liabilities			
Accounts payable	6 160 174	6 557 636	4 923 861
Other current liabilities	185 485	0	205 693
Current payable to group company	0	-236 705	0
Accrued expenses and deferred income	4 298 323	3 153 044	5 191 238
Total current liabilities	10 643 982	9 473 975	10 320 792
Total liabilities	10 643 982	9 473 975	10 320 792
Total Equity and Liabilities	69 959 183	56 643 411	80 685 955

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

19 November 2020

Q3 Quarterly Report

18 February 2021

2020 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktörgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.se
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se